MX2021010193A - Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. - Google Patents
Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.Info
- Publication number
- MX2021010193A MX2021010193A MX2021010193A MX2021010193A MX2021010193A MX 2021010193 A MX2021010193 A MX 2021010193A MX 2021010193 A MX2021010193 A MX 2021010193A MX 2021010193 A MX2021010193 A MX 2021010193A MX 2021010193 A MX2021010193 A MX 2021010193A
- Authority
- MX
- Mexico
- Prior art keywords
- azepino
- indoles
- heterocycles
- brain disorders
- treating brain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona azepino-indoles y otros heterociclos y métodos para usar los compuestos para tratar trastornos cerebrales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962811208P | 2019-02-27 | 2019-02-27 | |
PCT/US2020/019858 WO2020176599A1 (en) | 2019-02-27 | 2020-02-26 | Azepino-indoles and other heterocycles for treating brain disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010193A true MX2021010193A (es) | 2021-09-21 |
Family
ID=72238561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010193A MX2021010193A (es) | 2019-02-27 | 2020-02-26 | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. |
Country Status (14)
Country | Link |
---|---|
US (2) | US11414423B1 (es) |
EP (1) | EP3931189A4 (es) |
JP (1) | JP2022521789A (es) |
KR (1) | KR20210134689A (es) |
CN (1) | CN113784962A (es) |
AR (1) | AR119697A1 (es) |
AU (1) | AU2020229779A1 (es) |
BR (1) | BR112021016620A2 (es) |
CA (1) | CA3130770A1 (es) |
IL (1) | IL285649A (es) |
MX (1) | MX2021010193A (es) |
SG (1) | SG11202109111VA (es) |
TW (1) | TW202045477A (es) |
WO (1) | WO2020176599A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020228289A1 (en) | 2019-02-27 | 2021-09-09 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
AU2020229779A1 (en) | 2019-02-27 | 2021-09-09 | The Regents Of The University Of California | Azepino-indoles and other heterocycles for treating brain disorders |
GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
HRP20230281T1 (hr) | 2019-11-07 | 2023-04-28 | Small Pharma Ltd | Postupak sinteze |
KR20230012501A (ko) | 2020-05-19 | 2023-01-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
KR20230174210A (ko) * | 2021-02-08 | 2023-12-27 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 신경 및 정신 장애의 치료를 위한 옥사-이보게인 유사체 |
US20220354862A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Liposome delivery of psychedelics |
US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
US20230159544A1 (en) | 2021-10-29 | 2023-05-25 | Terran Biosciences, Inc. | Azepino-indoles for the treatment of neurological and psychiatric disorders |
WO2023092045A1 (en) * | 2021-11-17 | 2023-05-25 | Terran Biosciences, Inc. | Salt and solid forms of tabernanthalog |
WO2023212811A1 (en) * | 2022-05-06 | 2023-11-09 | Bright Minds Biosciences Inc. | Azepinoindoles and methods of preparation thereof |
WO2024052895A1 (en) | 2022-09-06 | 2024-03-14 | Hadasit Medical Research Services And Development Ltd | Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6515701A (es) | 1964-12-03 | 1966-06-06 | ||
US3525750A (en) | 1966-05-31 | 1970-08-25 | Geigy Chem Corp | 1,2,3,4,5,6-hexahydro-azepino(4,5-b) indole derivatives |
US3553232A (en) * | 1967-08-25 | 1971-01-05 | Upjohn Co | 4-(1,4,5,6-tetrahydroazepine(4,5-b)indole-3(2h)-yl)butyrophenones |
US3652588A (en) * | 1969-10-23 | 1972-03-28 | Upjohn Co | 6-alkyl-1 2 3 4 5 6-hexahydroazepino(4 5-b)indoles |
DE3070467D1 (en) | 1979-11-02 | 1985-05-15 | Sandoz Ag | Azepinoindoles, process for their production and pharmaceutical compositions containing them |
US4581354A (en) | 1984-08-06 | 1986-04-08 | Sterling Drug Inc. | 3-arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl-1H-indoles, compositions and use |
GB8419278D0 (en) | 1984-07-27 | 1984-08-30 | Lilly Industries Ltd | Pharmaceutical compounds |
DE3809155A1 (de) | 1988-03-18 | 1989-09-28 | Bayer Ag | 1,3,4,5-tetrahydrobenz-(c,d)-indole |
FR2674522B1 (fr) | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
DE4238994A1 (de) | 1992-11-19 | 1994-05-26 | Basf Ag | Aniline als Markierungsmittel für Mineralöle |
US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
TW270114B (es) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
GB9609641D0 (en) | 1996-05-09 | 1996-07-10 | Pfizer Ltd | Compounds useful in therapy |
AU6417198A (en) | 1997-03-13 | 1998-09-29 | Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency | Cytoprotective agents comprising monoamine oxidase inhibitors |
GB9819033D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
CA2356638A1 (en) | 1998-12-23 | 2000-07-06 | Nps Allelix Corp. | Indole and indolizidine derivatives for the treatment of migraine |
US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
AR023574A1 (es) | 1999-04-23 | 2002-09-04 | Pharmacia & Upjohn Co Llc | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios |
IL145998A0 (en) | 1999-06-15 | 2002-07-25 | Du Pont Pharm Co | Substituted heterocycle fused gamma-carbolines |
US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
MY122278A (en) | 1999-07-19 | 2006-04-29 | Upjohn Co | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
EP1263434A1 (en) | 2000-03-17 | 2002-12-11 | Alcon, Inc | Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma |
AU2001269781A1 (en) * | 2000-07-06 | 2002-01-21 | Pharmacia And Upjohn Company | Substituted 2,3,7,8,9,10,11,12-octahydroazepino(4,5-b)pyrano(3,2-e) indoles |
NZ523358A (en) | 2000-08-09 | 2004-09-24 | Astrazeneca Ab | Quinoline derivatives having VEGF inhibiting activity |
AU2001276521B2 (en) | 2000-08-09 | 2006-05-25 | Astrazeneca Ab | Cinnoline compounds |
US20070243240A9 (en) | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
US6583135B2 (en) | 2000-09-20 | 2003-06-24 | Pharmacia & Upjohn Company | Substituted azepino[4,5b]indole derivatives |
PL366233A1 (en) | 2000-12-20 | 2005-01-24 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
TW200400177A (en) | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
AU2003281361A1 (en) | 2002-07-09 | 2004-01-23 | Orient Chemical Industries, Ltd. | Nucleation effect inhibitor, crystalline resin composition and method of controlling crystallization of crystalline resin composition |
SG170617A1 (en) | 2003-01-16 | 2011-05-30 | Acadia Pharm Inc | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
US20050250767A1 (en) | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
JP2009513513A (ja) | 2003-07-04 | 2009-04-02 | グラクソスミスクライン・ソシエタ・ペル・アチオニ | Orl−1受容体リガンドとしての置換インドール |
EP1650206A4 (en) | 2003-08-01 | 2006-12-20 | Nippon Soda Co | PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS |
US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
US7772245B2 (en) | 2005-02-14 | 2010-08-10 | Miikana Therapeutics, Inc. | Inhibitors of histone deacetylase |
WO2007079239A2 (en) | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
JP5567349B2 (ja) | 2007-03-12 | 2014-08-06 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ−カルボリンの合成 |
WO2008117935A1 (en) | 2007-03-28 | 2008-10-02 | Industry-Academic Cooperation Foundation, Yonsei University | Nk cell activating molecules, nk cells and pharmaceutical compositons comprising the same |
US20090137598A1 (en) | 2007-06-21 | 2009-05-28 | Veroscience, Llc | Method of treating metabolic disorders and depression with dopamine receptor agonists |
JP2010534665A (ja) | 2007-07-25 | 2010-11-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメチックス、それらの製造方法、医薬組成物、及びこれらの使用 |
WO2009035473A2 (en) | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
WO2009103022A1 (en) | 2008-02-13 | 2009-08-20 | Itherx Pharmaceuticals, Inc. | Derivatives of substituted fused ring cycloindoles and methods of their use |
CN104387382A (zh) * | 2008-03-24 | 2015-03-04 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚和应用方法 |
AR073924A1 (es) * | 2008-10-31 | 2010-12-09 | Medivation Technologies Inc | Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina. |
CN102405043B (zh) | 2009-01-09 | 2017-08-22 | 得克萨斯州大学系统董事会 | 前神经原性化合物 |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
EP2448585B1 (en) | 2009-07-01 | 2014-01-01 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
US8367655B2 (en) | 2009-07-03 | 2013-02-05 | Daya Drug Discoveries, Inc. | Pyridoindolobenzox—and thiazepine derivatives and uses thereof |
EP2526500A2 (en) | 2010-01-18 | 2012-11-28 | Elminda Ltd. | Method and system for weighted analysis of neurophysiological data |
WO2012144972A2 (en) | 2010-01-19 | 2012-10-26 | The General Hospital Corporation | Methods to inhibit neurodegeneration |
US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
US9393198B2 (en) | 2010-03-22 | 2016-07-19 | Signpath Pharma Inc. | Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders |
WO2011123681A1 (en) | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
JP2014505737A (ja) | 2011-02-18 | 2014-03-06 | メディベイション テクノロジーズ, インコーポレイテッド | 糖尿病を処置する化合物および方法 |
US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
US20130178618A1 (en) | 2012-01-10 | 2013-07-11 | William Allen Boulanger | Novel pharmaceutical intermediates and methods for preparing the same |
US10118943B2 (en) | 2012-05-16 | 2018-11-06 | Ramot At Tel-Aviv University Ltd. | Compounds and methods for inhibiting cell death |
CN102977092B (zh) | 2012-11-06 | 2016-02-24 | 华东师范大学 | 芳香烷酰基四氢-β-咔啉及其衍生物在治疗恶性肿瘤中的应用 |
CN102977091B (zh) | 2012-11-06 | 2016-03-09 | 华东师范大学 | 芳香烷酰基四氢-β-咔啉及其衍生物在治疗代谢性疾病中的应用 |
US9822117B2 (en) | 2013-03-04 | 2017-11-21 | Daya Drug Discoveries, Inc. | Pyridoindolobenz[b,d]azepine derivatives and uses thereof |
CN105143190B (zh) | 2013-03-14 | 2017-08-18 | 达特神经科学(开曼)有限公司 | 作为mao抑制剂的被取代的萘啶和喹啉化合物 |
SG11201504709PA (en) | 2013-03-14 | 2015-07-30 | Dart Neuroscience Llc | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
WO2017053886A2 (en) | 2015-09-23 | 2017-03-30 | Minerva Biotechnologies Corporation | Method of screening for agents for differentiating stem cells |
GB2550110A (en) | 2016-04-28 | 2017-11-15 | Univ Oxford Innovation Ltd | Treatment of impulsivity-related disorders |
WO2017216279A1 (en) | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | Heteroaryl estrogen receptor modulators and uses thereof |
AU2017321708B2 (en) | 2016-08-31 | 2024-01-04 | Rutgers, The State University Of New Jersey | Methods and compositions for treating diseases and disorders of the nervous system |
US20200030309A1 (en) | 2016-09-29 | 2020-01-30 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
CA3105451A1 (en) | 2017-05-12 | 2018-11-15 | Indiana University Research And Technology Corporation | Precision medicine for treating and preventing suicidality |
US11845742B2 (en) | 2017-11-14 | 2023-12-19 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods to treat infection |
TWI743484B (zh) * | 2018-06-04 | 2021-10-21 | 瑞士商Ac免疫公司 | 用於治療、改善或預防與tau聚集物相關之病症的新穎化合物 |
CN114423422A (zh) | 2019-02-22 | 2022-04-29 | Gh研究爱尔兰有限公司 | 用于治疗精神障碍的含有5-甲氧基-n,n-二甲基色胺(5-meo-dmt)的组合物 |
AU2020229779A1 (en) | 2019-02-27 | 2021-09-09 | The Regents Of The University Of California | Azepino-indoles and other heterocycles for treating brain disorders |
AU2020228289A1 (en) | 2019-02-27 | 2021-09-09 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
EP3934652A4 (en) | 2019-03-05 | 2022-12-07 | F-Star Therapeutics, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES |
CN114025750A (zh) | 2019-03-07 | 2022-02-08 | 阿伯门蒂斯有限责任公司 | 包含神经可塑性作用物质的以非迷幻/致幻觉剂量和制剂给药的组合物和使用方法 |
CN114901279A (zh) | 2019-03-13 | 2022-08-12 | 洛克菲勒大学 | 用于治疗自身炎性疾病和癌症转移的cGAS的抑制剂 |
US20230295106A1 (en) | 2019-10-14 | 2023-09-21 | The Regents Of The University Of California | Ergoline-like compounds for promoting neural plasticity |
-
2020
- 2020-02-26 AU AU2020229779A patent/AU2020229779A1/en active Pending
- 2020-02-26 WO PCT/US2020/019858 patent/WO2020176599A1/en unknown
- 2020-02-26 SG SG11202109111VA patent/SG11202109111VA/en unknown
- 2020-02-26 EP EP20763824.8A patent/EP3931189A4/en active Pending
- 2020-02-26 CA CA3130770A patent/CA3130770A1/en active Pending
- 2020-02-26 CN CN202080017483.XA patent/CN113784962A/zh active Pending
- 2020-02-26 MX MX2021010193A patent/MX2021010193A/es unknown
- 2020-02-26 JP JP2021549987A patent/JP2022521789A/ja active Pending
- 2020-02-26 BR BR112021016620A patent/BR112021016620A2/pt unknown
- 2020-02-26 KR KR1020217030793A patent/KR20210134689A/ko unknown
- 2020-02-27 TW TW109106545A patent/TW202045477A/zh unknown
- 2020-02-27 AR ARP200100542A patent/AR119697A1/es unknown
-
2021
- 2021-06-11 US US17/345,745 patent/US11414423B1/en active Active
- 2021-08-16 IL IL285649A patent/IL285649A/en unknown
-
2022
- 2022-07-12 US US17/862,646 patent/US20230117791A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR119697A1 (es) | 2022-01-05 |
EP3931189A4 (en) | 2022-11-30 |
CN113784962A (zh) | 2021-12-10 |
WO2020176599A1 (en) | 2020-09-03 |
US20230117791A1 (en) | 2023-04-20 |
EP3931189A1 (en) | 2022-01-05 |
TW202045477A (zh) | 2020-12-16 |
AU2020229779A1 (en) | 2021-09-09 |
KR20210134689A (ko) | 2021-11-10 |
JP2022521789A (ja) | 2022-04-12 |
IL285649A (en) | 2021-09-30 |
SG11202109111VA (en) | 2021-09-29 |
CA3130770A1 (en) | 2020-09-03 |
BR112021016620A2 (pt) | 2021-11-03 |
US11414423B1 (en) | 2022-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
MX2021010198A (es) | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. | |
MX2022002877A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. | |
MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
EP3746135A4 (en) | METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
EA201890256A1 (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
MX2020003593A (es) | Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos. | |
MY196448A (en) | Anti-Htra1 Antibodies and Methods of use Thereof | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
PH12018500736A1 (en) | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity | |
IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
MX2021003903A (es) | Terapia combinada para el melanoma. | |
MX2021003450A (es) | Metodos para tratar trastornos mieloproliferativos. | |
MX2021006831A (es) | Inhibidores de alk5. | |
EP3826650A4 (en) | METHODS OF TREATMENT OF NEUROLOGICAL DISEASES | |
MX2021003515A (es) | Compuestos polimorficos y usos de los mismos. | |
IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
MX2017014782A (es) | Metodo para el tratamiento de enfermedad neurologica. | |
EP3826649A4 (en) | METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS | |
MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
MX2019009304A (es) | Tratamiento para el cancer. |